SEC Form 4	
------------	--

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

L											
	OMB Number:	3235-0287									
	Estimated average burden										
	hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

			or design bo(ii) of the investment company rise of 1540				
1. Name and Addre <u>Young Jonat</u>	ss of Reporting Pers 1an	on*	2. Issuer Name and Ticker or Trading Symbol <u>Akero Therapeutics, Inc.</u> [AKRO]		ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner		
	st) (First) (Middle) O AKERO THERAPEUTICS, C., 170 HARBOR WAY, 3RD FLOOR		3. Date of Earliest Transaction (Month/Day/Year) 03/13/2020	X	Officer (give title below) Chief Operating	Other (specify below) Officer	
(Street) SOUTH SAN FRANCISCO (City)	CA (State)	94080 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing Form filed by One Repo Form filed by More that Person	orting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 Non Derivative Occurrices Acquired, Disposed 61, 61 Derenolarly Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	03/13/2020		М		5,035	A	\$0.615	177,518 ⁽¹⁾	D		
Common Stock	03/13/2020		М		6,082	A	\$0.615	183,600(1)	D		
Common Stock								20,000	I	By EA Irrevocable Trust ⁽²⁾	
Common Stock								20,000	I	By CM Irrevocable Trust ⁽²⁾	
Common Stock								20,000	I	By JL Irrevocable Trust ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4			
Stock Option (Right to Buy)	\$0.615	03/13/2020		М			5,035	(3)	07/29/2028	Common Stock	5,035	\$0	42,796	D	
Stock Option (Right to Buy)	\$0.615	03/13/2020		М			6,082	(4)	10/17/2028	Common Stock	6,082	\$0	94,268	D	

Explanation of Responses:

1. Due to a clerical error in the preparation of the reporting person's Form 3, the reporting person's beneficial ownership was overstated by 60,000 on the Form 3 filed on June 19, 2019 and the Form 4s filed on December 31, 2019 and January 10, 2019 as the 60,000 shares that are indicated as being owned by the EA Irrevocable Trust, CM Irrevocable Trust and JL Irrevocable Trust were not removed from the reporting person's direct ownership total reported in column 5. That error has been corrected in this Form 4.

2. These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. 25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.

4. Shares vested and became exercisable in equal monthly installments for a period of 48 months following October 1, 2018.

<u>/s/ Jonathan Young</u>

** Signature of Reporting Person

03/16/2020 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.